Conventionally fractionated stereotactic radiotherapy (CFRT) in combination with dose-dense temozolomide (TMZ) in relapsed malignant glioma: A case report

Medicine (Baltimore). 2019 Jan;98(1):e13869. doi: 10.1097/MD.0000000000013869.

Abstract

Rationale: At present, there is no uniform consensus on the treatment of recurrent glioblastoma, especially the re-irradiation dose and temozolomide (TMZ) dose. The literature on the treatment of recurrent glioblastoma (GBM) by conventionally fractionated stereotactic radiotherapy (CFRT) is even rarer.

Patient concerns: A 44-year-old woman was admitted to our hospital for residual tumor after reoperation.

Diagnoses: Postoperative pathological diagnosis was GBM, WHO grade IV. The brain magnetic resonance imaging re-examination showed abnormal enhancement around the local operative region after resection of the left frontal lobe tumor, and there was presence of residual tumor.

Interventions: The patient was treated with reoperation followed by re-irradiation plus dose-dense TMZ to achieve complete remission.

Outcomes: Complete remission was observed at the end of radiotherapy and at the 1 month follow-up after radiotherapy.

Lessons: This study suggests that CFRT plus dose-dense TMZ might be a feasible option for the treatment in relapsed malignant glioma patients with good general condition.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents, Alkylating / therapeutic use*
  • Brain Neoplasms / therapy*
  • Combined Modality Therapy
  • Female
  • Glioblastoma / therapy*
  • Humans
  • Neoplasm Grading
  • Neoplasm Recurrence, Local
  • Radiation Dosage
  • Radiosurgery / methods*
  • Reoperation / methods
  • Temozolomide / therapeutic use*

Substances

  • Antineoplastic Agents, Alkylating
  • Temozolomide